What were the key financial results for Bristol Myers Squibb in the third quarter of 2022?

The 10-Q filing provides detailed financial statements including the Consolidated Statements of Earnings and Comprehensive Income, Balance Sheets, and Cash Flows, which outline the company's revenue, profitability, assets, liabilities, and cash movements for the period ending September 29, 2022. Investors should refer to Item 1 for these specific figures.

What are the main risks and challenges Bristol Myers Squibb is facing?

Item 1A, Risk Factors, outlines potential risks such as competition, patent expirations, regulatory changes, clinical trial failures, and litigation. Investors should carefully review this section to understand the potential headwinds the company may encounter.

Are there any significant legal proceedings that could impact BMY?

Item 1, Legal Proceedings, details any ongoing lawsuits or regulatory actions that Bristol Myers Squibb is involved in. This section is crucial for understanding potential financial liabilities or operational disruptions arising from legal matters.

Where can I find management's perspective on the company's performance and outlook?

Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, provides management's narrative on the company's financial performance, liquidity, capital resources, and future prospects. This section offers valuable qualitative insights beyond the raw financial numbers.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q3 FY2022

Summary

Bristol Myers Squibb (BMY) filed its 10-Q for the period ending September 29, 2022, reporting on its financial performance and operational developments. Investors should note the company's continued focus on its product portfolio and strategic growth initiatives. The filing provides a detailed look at the company's financial health, including its revenues, expenses, and cash flows, as well as an overview of significant factors that may impact future performance. Key areas to monitor include the performance of their key drugs, ongoing research and development efforts, and any updates on legal proceedings or risk factors that could affect the business.

Financial Highlights

57 data points

Beta

Revenue

$11.22B

0.8% Gross Margin

Net Income

$1.61B

0.1% Net Margin

EPS (Diluted)

$0.75

Total Assets

$98.20B

Cash & Equivalents

$7.73B

Free Cash Flow

$3.44B

Financial Statements

Beta

Revenue	$11.22B
Cost of Revenue	$2.35B
Gross Profit	$8.87B
R&D Expenses	$2.42B
SG&A Expenses	$1.93B
Operating Expenses	$9.01B
Interest Expense	$299.00M
Net Income	$1.61B
EPS (Basic)	$0.75
EPS (Diluted)	$0.75
Shares Outstanding (Basic)	2.13B
Shares Outstanding (Diluted)	2.15B

Key Highlights

1Consolidated Statements of Earnings and Comprehensive Income, Balance Sheets, and Cash Flows provide the core financial performance and position for the period.
2Management's Discussion and Analysis offers insights into the company's operational results, financial condition, and future outlook.
3The filing includes an update on Legal Proceedings, which can be material to the company's financial and operational stability.
4Risk Factors section details potential challenges and uncertainties that could impact BMY's future performance, essential for risk-aware investors.
5Quantitative and Qualitative Disclosure About Market Risk provides information on how BMY manages its exposure to financial market risks.
6Item 4 focuses on Controls and Procedures, indicating the company's commitment to internal financial reporting integrity.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q3 Ended Sep 30, 2022

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions